Heart Transplantation and MCS in Advanced Heart Failure

Published on 2017-11-17853 Views

Igor Gregorič

Pri srčnem popuščanju srce ne more več prečrpavati dovolj velike količine krvi po telesu za presnovne potrebe, zato so organi slabo preskrbljeni s kisikom in hranilnimi snovmi. Neustrezna prekrvitev o

Znanstveni večeri UNG

Related categories

Medicine

Presentation

Heart Transplantation and MCS in Advanced Heart Failure00:00

CVD deaths vs. cancer deaths by age (US)06:31

Hospital Discharges (in millions)06:54

Heart Failure Facts07:07

Etiologies of heart failure07:52

HF Mortality associated with Continuous Inotropic Infusions08:06

End Stage Heart Failure08:20

Heart failure09:29

Heart Transplantation - 109:48

Christian Barnard10:39

Heart Transplantation - 211:52

Summary of Heart Transplants11:57

Richenbacher, MCS, 199912:30

1976 – Discovery Cyclosporine A13:23

Most Common Transplantation14:07

Immunologic Analysis14:12

Technique - 115:18

Technique - 215:21

Technique - 315:34

Heart Transplantation - 315:47

Adult and Pediatric Heart Transplants - 115:50

Adult and Pediatric Heart Transplants - 216:35

Adult and Pediatric Heart Transplants - 316:41

Adult Heart Transplants - 118:28

Adult Heart Transplants - 218:33

Rejection18:42

Grade 3R, Severe (3B)19:05

Adult Heart Transplants - 319:38

Adult Heart Transplants - 420:16

Adult Heart Transplants - 520:25

Adult Heart Transplants - 620:32

Adult Heart Transplants - 720:45

Adult Heart Transplants - 820:46

Adult Heart Transplants - 920:47

Adult Heart Transplants - 1021:00

Sleh 198721:16

MCS in Chronic Heart Failure21:52

First Clinical LVAD22:06

First Clinical LVAD Success - 122:48

First Clinical LVAD Success - 223:14

Mid 80’s23:22

First generation Pulsatile Devices for Long Term Use - 123:48

First generation Pulsatile Devices for Long Term Use - 224:17

First generation Pulsatile Devices for Long Term Use - 324:46

HeartMate XVE - 125:08

HeartMate XVE - 225:39

HeartMate XVE - 326:05

Working With HM I26:32

First FDA Approved Device for Destination Therapy26:41

Rematch27:01

Axial flow second generation LVAD’s28:05

New Technology28:09

Axial Flow Pumps28:28

DeBakey/NASA29:06

DeBakey VAD Pump29:16

Implantation of the Jarvik 200029:44

Different Surgical Approaches30:04

Home Discharge Experience30:07

Portret30:24

HeartMate II - 130:56

HMII Anatomical Placement31:18

Original Article31:20

Actuarial Survival vs REMATCH31:23

Patient Quality of Life31:52

HeartMate II - 232:02

HeartMate II - 332:09

Third Generation Blood Pumps33:08

DuraHeart LVAD33:20

The world’s first commercially available Mag-Lev33:22

DuraHeart External Components33:25

DuraHeart Long Term Biocompatibility33:42

HeartWare LVAD34:11

HeartWare LVAS34:36

Evaluation of the HeartWare34:45

ADVANCE Trial Secondary Outcome: Survival34:48

MCS Complications35:22

Perioperative Bleeding35:25

Pericardial Placement with no pocket – a Key Advantage35:41

Blood transfusion35:53

Driveline infection36:19

Infection - 136:24

Infection - 236:38

Importance of Nutrition36:56

TET systems37:05

GI Bleeding37:26

GI bleeding/AVMs37:57

Patients and Methods38:58

AVMs stomach39:03

Pump Thrombosis39:42

LVAD Thrombosis39:49

Non Pump related Thrombosis of LVAD40:13

Dislodgement of outflow cannula40:16

Pump replacement40:20

Disconnected Bend relief graft40:40

HeartMate-II Outflow Graft and Bend Relief40:43

OBR damage to graft during exposure for Heart Transplant40:56

Normal connection41:08

Evolution of LVAD Technology41:11

Pump related Thrombosis of LVAD41:12

Bearings – Potentially heat generated in this area - 141:19

Bearings – Potentially heat generated in this area - 241:45

Blood Damage41:47

Hemolysis41:51

Platelet Trajectories - 142:07

Platelet Trajectories - 242:09

Platelet Trajectories - 342:11

Platelet Trajectories - 442:23

Platelet Trajectories - 542:28

Platelet Trajectories - 642:46

Platelet Trajectories - 742:53

Platelet Trajectories - 843:00

Platelet Trajectories - 943:01

Findings43:04

Clinical studies43:17

H-Vad43:29

Endurance trial - 143:37

Endurance trial - 243:41

Endurance trial - 343:52

Prevent - 144:22

Prevent - 244:26

Algorithm for the Diagnosis and Management of Pump Thrombosis44:35

Prevent - 344:46

Results44:54

Conclusion45:14

New LVAD Trials45:41

HM III45:43

HeartMate III: Design Goals45:57

A Healthy Respect for the Blood46:00

Design Configuration46:17

HeartMate III: Full MagLev Technology46:23

How much difference is there?46:33

HeartMate III: Artificial Pulse46:52

Future47:07

Miniature VAD Development47:18

Future LVADs47:24

Center for Advanced Heart Failure Research Division47:43

Thank You47:59